Cathflo® Activase® (alteplase) 2–mg vial of t–PA

FDA-approved and marketed for restoration of CVAD function
Available in a single-use, 2-mg vial
Efficacy and safety profile in adult and pediatric patients of all ages5,6

Indication

Cathflo Activase (Alteplase) is indicated for the restoration of function to central venous access devices (CVADs) as assessed by the ability to withdraw blood.

Safety Information

Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation.

In clinical trials, the most serious adverse events reported after treatment were sepsis, gastrointestinal bleeding, and venous thrombosis. Cathflo Activase should be used with caution in the presence of known or suspected infections in the catheter.

Please click here for full prescribing information.

Order useful tools to help you in your clinical practice

View a brief MOA video now

References:

Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion? JPEN Parenter Enteral Nutr. 1995;19(1):75-79.
National Institutes of Health. Management of central venous catheter occlusions. Pharm Update. 1999:1-4.
Hadaway LC. Reopen the pipeline for I.V. therapy. Nursing. 2005;35(8):54-61.
Mayo DJ, Pearson DC. Chemotherapy extravasation: a consequence of fibrin sheath formation around venous access devices. Oncol Nurs Forum. 1995;22(4):675-680.
Deitcher SR, Fesen MR, Kiproff PM, et al, for the Cardiovascular Thrombolytic to Open Occluded Lines-2 Investigators. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the Cardiovascular Thrombolytic to Open Occluded Lines trial. J Clin Oncol. 2002;20:317-324.
Blaney M, Shen V, Kerner JA, for the CAPS Investigators. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (the Cathflo Activase Pediatric Study). J Vasc Interv Radiol. 2006;17:1745-1751.